Articles

  • 1 week ago | peoplespharmacy.com | Joe Graedon |Alzheimer’s disease

    For decades researchers have considered nicotine a serious health problem. It is, after all, the addicting compound in cigarettes and other tobacco products. Humans have apparently been using tobacco as a drug for over 12,000 years (Nature Human Behavior, Feb. 2022). It has been smoked, snuffed and chewed. More recently, drug companies have created the nicotine patch. It is supposed to help people stop smoking. Could it also help people who are suffering from Alzheimer disease?

  • 2 months ago | inforum.com | Lonna Whiting |Alzheimer’s disease

    Anshul Roy began his journey as an artist as a traditional photographer attracted to the romantic notions of seeing the world with new eyes, finding beauty in the mundane and capturing it for the world to see and remember forever. All that changed when he realized capturing images for the world to see and remember also meant documenting some of the worst in humanity at the same time.

  • Jan 23, 2025 | peoplespharmacy.com | Terry Graedon |Alzheimer’s disease

    Many people would like more information on how to prevent dementia. Perhaps they have taken care of a family member during a long, slow decline. Or maybe they have watched a neighbor or friend gradually lose their ability to think or interact. Luckily, there are several simple steps we can take to stay sharp. Most will not surprise you–regular exercise, healthful diet, avoid toxins and brain injury. But one factor surprised us. Can Controlling the Thermostat Help You Prevent Dementia?

  • Jan 22, 2025 | link.springer.com | del Val |Josep Maria |Alzheimer’s disease |Universitat de Barcelona

    AbstractPlasma tau phosphorylated at threonine 181 (p-tau181) and 217 (p-tau217) have demonstrated high accuracy for Alzheimer’s disease (AD) diagnosis, defined by CSF/PET amyloid beta (Aβ) positivity, but most studies have been performed in research cohorts, limiting their generalizability. We studied plasma p-tau217 and p-tau181 for CSF Aβ status discrimination in a cohort of consecutive patients attending an academic memory clinic in Spain (July 2019–June 2024).

  • Jan 22, 2025 | peoplespharmacy.com | Joe Graedon |Alzheimer’s disease

    Visitors to this website and subscribers to our newsletter know that we have been highly critical of the FDA’s approval of anti-amyloid drugs for Alzheimer’s disease (AD). They are expensive, barely beneficial at slowing cognitive decline and have some serious side effects. There is growing support for a different approach to AD. We were intrigued to read a new systematic review of medications and dementia (Translational Research & Clinical Interventions, Jan. 21, 2025).

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →